Safety Evaluation of Linear and Macrocyclic Gadolinium Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging

Last updated: February 26, 2021
Sponsor: The Central Hospital of Lishui City
Overall Status: Active - Recruiting

Phase

4

Condition

Kidney Disease

Nephropathy

Kidney Failure (Pediatric)

Treatment

N/A

Clinical Study ID

NCT04776187
Gadolinium 1.0
  • Ages 18-80
  • All Genders

Study Summary

The purpose of this study is to evaluate the safety of linear and macrocyclic gadolinium-based contrast agents for patients with mild to moderate renal insufficiency. The study will compare the incidence of adverse events of gadodiamide and gadoteric Acid Meglumine Salt for patients with mild to moderate renal insufficiency undergoing enhanced magnetic resonance imaging.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Patients aged 18 to 80 years old who require gadolinium-based CE-MRI;
  2. Patients with renal function 30ml/min/1.73m2≤eGFR<90/min/1.73m2;
  3. Patients who are able and willing to comply with the required inspection requirements.

Exclusion

Exclusion Criteria:

  1. Patient who experienced allergic reactions to previous gadolinium-based contrastagents;
  2. Patient who had used gadolinium-based contrast agents within 3 months;
  3. Patient with acute renal failure;
  4. Patient who cannot comply with or cannot tolerate the necessary fluid replenishmentprocedures;
  5. Patient with major mental illness, impaired consciousness, or other diseasesconsidered by researchers to affect observation.

Study Design

Total Participants: 600
Study Start date:
March 01, 2021
Estimated Completion Date:
December 31, 2021

Study Description

According to the requirements of the study, 600 cases of patients with mild to moderate renal insufficiency were enrolled. Gadodiamide and Gadoteric acid meglumine salt were used for enhanced MRI. Observe the adverse reactions within 60 minutes of using the gadolinium contrast agents; follow up by telephone at 3, 6, 12, and 24 months after the inspection. The primary endpoint is the incidence of the various adverse events, and the secondary endpoints are changes of serum creatinine and inflammatory factors (TNF-α, hs-CRP, IL-6) before and after CE-MRI, patient skin examination and evaluation (evaluation of relevant indicators of skin biopsy).

Connect with a study center

  • Lishui Central Hospital

    Lishui, Zhejiang 323000
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.